Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Choline + zolpidem appears to denote a **combination product or co-administration concept** involving choline and zolpidem for insomnia, rather than a well-established, uniquely identified approved pharmaceutical product. In the provided context, the only clearly supported active pharmaceutical ingredient is **zolpidem**, a nonbenzodiazepine sedative-hypnotic that acts as a positive allosteric modulator at the benzodiazepine site of the **gamma-aminobutyric acid type A receptor**, with relative selectivity for receptor complexes containing the alpha1 subunit, thereby promoting sleep initiation. Choline is a nutritional compound and precursor for phosphatidylcholine and acetylcholine, but no specific validated therapeutic insomnia mechanism or distinct marketed fixed-dose drug identity for the exact combination was established from the supplied material.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on choline + zolpidem.